How do I prevent ghost promoters in my mall activation campaigns in 2026?
2 min read
The Field Execution Intelligence playbook for pharma field force operations in India
A vertical playbook for India's $65B pharma sector and its 600,000+ medical representatives. Built for Sales Excellence heads, Field Force Operations leaders, and pharma CXOs running doctor coverage, chemist engagement, sample distribution, and prescription conversion across India.
30 to 40%
Visit adherence rate observed across mid-tier Indian pharma field forces. The gap between planned doctor calls and actually completed visits is the single largest hidden cost line in Indian pharma sales operations.
$65B+India pharma market 2024
$130BProjected 2030
600,000+Medical Representatives
1.2M+Doctors targeted nationally
A National Sales Manager at a top-10 Indian pharma company opens Monday's regional review. 14,200 doctor calls reported last week. The dashboard shows 96% MTP adherence. Prescription audit data from chemists tells a different story. Coverage in three high-potential territories looks identical to coverage in low-priority pockets. The reported numbers and the ground reality are no longer reconciling.
The Indian pharma field execution map
| Operational layer | India scale | Verification maturity |
|---|---|---|
| Medical Representatives (MRs) | 600,000+ | Low (DCR-based self-report) |
| Area Business Managers / First Line Managers | 55,000 to 70,000 | Low (review-cycle dependent) |
| Regional Sales Managers | 8,000 to 12,000 | Medium |
| Doctors (target HCPs) | 1.2 million+ | Medium (master data quality varies) |
| Specialist doctors (priority targets) | 320,000 to 400,000 | Higher (focused coverage) |
| Retail chemists | 900,000+ | Low |
| Hospitals (private and government) | 69,000+ | Medium |
| Distributors / stockists | 65,000+ | Medium (DMS-driven) |
| Sample stock units (per company per quarter) | 5 to 50 million | Low (distribution unverified) |
| Daily Call Reports submitted nationally | ~5 million per day | Low (self-reported) |
Daily activity benchmarks for an average MR
| Activity | Typical daily target | Actual baseline |
|---|---|---|
| Doctor calls per day | 10 to 14 | 6 to 9 verified |
| Chemist visits per day | 5 to 8 | 3 to 5 verified |
| Stockist visits per week | 2 to 4 | 1 to 3 |
| Average call duration with doctor | 5 to 8 minutes | 2 to 4 minutes |
| RCPA conducted per week | 3 to 5 | 1 to 2 |
| Sample packs distributed per week | 40 to 80 | Reported high, verified low |
| e-detailing sessions per week | 15 to 25 | 8 to 14 |
| POB transactions per month | 30 to 60 | Variable by territory |
The 5-layer FEI stack for pharma field force
1
Territory and visit verification
Geo-fenced clinic and chemist verification, EXIF preserved capture, sensor cross-check confirming actual presence, MTP adherence tracking. Replaces self-reported DCR with verified call records.
2
Authenticity and anti-spoofing
9-layer mock-location detection, face match selfie at clinic entry, duplicate visit flagging, batch submission detection. Catches geo-spoofed check-ins and shared-device fraud.
3
Prescription correlation intelligence
Links MR visits, sample drops, RCPA findings, and chemist engagement with prescription lift per doctor, per territory, per molecule. Converts activity data into commercial signal.
4
Compliance and audit infrastructure
UCPMP-aligned audit trails, content compliance logging, sample reconciliation, regulatory documentation retention. The regulatory layer for a sector under MCI, NPPA, CDSCO, and DPCO scrutiny.
5
Sales Excellence and CFO accountability
Verified call rate as KPI, productive call effectiveness, vendor scorecards, BRSR Core ready audit trail. Brings pharma field spend to procurement-grade governance.
10 pharma-specific field execution fraud patterns
Ghost doctor calls
MR marks doctor as visited without entering clinic. Sensor cross-check and door-side geo-fence catch the gap.
Pattern 01
Pattern
Batch end-of-day DCR filing
All 12 doctor calls logged between 6 to 8 PM from one location. Continuous capture exposes the timing pattern.
Pattern 02
Pattern
Mock-location DCR
MR submits DCR from home using fake GPS apps. 9-layer detection catches 99%+ of attempts.
Pattern 03
Pattern
Proxy chemist visits
Single MR check-in covers multiple chemists in same complex without actual entry. Per-shop boundary verification surfaces the issue.
Pattern 04
Pattern
Fake doctor master data
Non-existent doctors added to coverage lists for inflated call counts. OTP plus MCI registration cross-check eliminates the path.
Pattern 05
Pattern
Sample distribution unverified
Samples billed as distributed are routed elsewhere. Outlet-level sample drop reconciliation closes the loop.
Pattern 06
Pattern
Call duration inflation
2-minute corridor conversations logged as 8-minute detailing sessions. Continuous timer with location lock verifies duration.
Pattern 07
Pattern
Territory boundary violation
MR poaches doctors from neighboring territories for personal targets. Territory geo-fence flags the cross-over.
Pattern 08
Pattern
RCPA fabrication
Retail Chemist Prescription Audit numbers invented without actual audit. Photo evidence requirement plus chemist OTP catches it.
Pattern 09
Pattern
POB inflation in low-season
Prescription Order Booking numbers spike in low-season to clear targets. Stockist reconciliation surfaces the disconnect.
Pattern 10
Pattern
DCR integrity: the operational gap
The gap between reported and verified field activity is the single largest unmeasured cost line in Indian pharma sales operations. It manifests as lower prescription lift per ₹ of field spend, not as a missing expense.
| DCR integrity dimension | Self-reported baseline | FEI-verified baseline |
|---|---|---|
| MTP adherence (% of planned calls completed) | 88 to 96% | 62 to 78% |
| Productive call rate | 72 to 84% | 52 to 68% |
| High-potential doctor coverage | 85 to 92% | 64 to 76% |
| Average call duration | 6 to 8 minutes | 2.5 to 4 minutes |
| RCPA accuracy | Self-reported 100% | Verified at 68 to 80% |
| Sample distribution accuracy | 95 to 99% claimed | 72 to 84% verified |
| Territory route adherence | 82 to 90% | 68 to 80% |
| Real-time DCR submission | Reported real-time | ~38% submitted within 2 hours of visit |
Doctor coverage architecture: A, B, C, D classification
| Doctor tier | Definition | Target call frequency | Actual coverage gap |
|---|---|---|---|
| A (top potential) | Top 10% prescribers in territory | 4 to 6 calls/month | 22 to 32% under-coverage |
| B (high potential) | Next 20% prescribers | 2 to 3 calls/month | 18 to 26% |
| C (medium potential) | Next 40% prescribers | 1 to 2 calls/month | 14 to 22% |
| D (low potential) | Bottom 30% | Quarterly or skip | Often over-covered |
The hidden mis-allocation in pharma field force
| Allocation pattern | Reported intent | Actual ground reality |
|---|---|---|
| A-grade doctor focus | 70 to 80% of MR time | 45 to 58% |
| B-grade doctor focus | 15 to 22% | 20 to 25% |
| C-grade doctor focus | 5 to 10% | 15 to 20% |
| D-grade doctor focus | 0 to 3% | 7 to 12% |
| Effective high-potential territory coverage | 92%+ claimed | 64 to 76% verified |
Territory leakage exposure across pharma categories
| Therapy area | Field force size (typical large brand) | Annual field operating cost | Leakage exposure |
|---|---|---|---|
| Cardiac and metabolic | 1,200 to 2,500 MRs | ₹120 to 280 Cr | ₹18 to 50 Cr |
| Diabetic | 800 to 1,800 MRs | ₹85 to 190 Cr | ₹13 to 35 Cr |
| Anti-infective | 1,500 to 3,000 MRs | ₹150 to 320 Cr | ₹22 to 60 Cr |
| Gastro | 600 to 1,400 MRs | ₹65 to 140 Cr | ₹10 to 26 Cr |
| Oncology | 200 to 600 MRs (specialist) | ₹30 to 80 Cr | ₹3 to 12 Cr |
| CNS / neuro | 400 to 1,000 MRs | ₹40 to 100 Cr | ₹6 to 18 Cr |
| Gynecology | 500 to 1,200 MRs | ₹55 to 130 Cr | ₹8 to 25 Cr |
| Pediatric | 400 to 900 MRs | ₹40 to 95 Cr | ₹6 to 18 Cr |
| Dermatology | 300 to 700 MRs | ₹30 to 75 Cr | ₹4 to 14 Cr |
| Ortho and pain | 500 to 1,100 MRs | ₹50 to 110 Cr | ₹7 to 20 Cr |
See actual field coverage vs reported coverage
Bring one division or one therapy team for a 14-day pilot. We deploy the 5-layer FEI stack passively. You receive a verified DCR audit, territory coverage gap report, and sample reconciliation summary. Free, no setup required for M₹
Request a pharma coverage audit →RCPA intelligence: from audit to insight
| RCPA practice | Pre-FEI workflow | FEI workflow |
|---|---|---|
| Frequency | Weekly self-reported | Weekly verified at chemist |
| Photo evidence | Optional / inconsistent | Prescription pad photo with chemist OTP |
| Competitor visibility | Anecdotal mentions | SKU-level facing count |
| Brand share movement | Quarterly review | Weekly trend per molecule |
| Chemist credibility scoring | None | Chemist-level audit reliability score |
| Cross-territory comparison | Manual collation | Real-time benchmarking |
| Action loop closure | Verbal in monthly review | Auto-task to ABM for high-variance accounts |
| Audit-grade documentation | Excel sheets | 7-year structured retention |
Prescription correlation: linking activity to outcome
| Activity signal | Outcome metric | Correlation enabled by FEI |
|---|---|---|
| Verified doctor calls per month | Prescriptions per doctor | Per-doctor call-to-Rx coefficient |
| Sample drops per doctor | Trial Rx volume | Sample-to-trial conversion rate |
| Detailing call duration | Brand share movement | Effective call quality score |
| RCPA findings | Territory share trend | Audit-derived growth signal |
| Chemist engagement | POB and secondary sales | Pull-through effectiveness |
| Coverage frequency by tier | Tier-wise Rx growth | Allocation effectiveness |
| Speciality focus time | Speciality-specific Rx | Channel productivity |
| New doctor onboarding | First Rx within 60 days | Onboarding ROI |
Sales Excellence KPI scorecard for pharma operations
| SFE KPI | Pre-FEI baseline | FEI-enabled target |
|---|---|---|
| Verified MTP adherence | 62 to 78% | 88 to 94% |
| Productive call rate | 52 to 68% | 72 to 85% |
| A-grade doctor coverage | 64 to 76% | 88 to 95% |
| Average call duration | 2.5 to 4 minutes | 5 to 7 minutes |
| Real-time DCR submission rate | 38% | 88 to 94% |
| Sample distribution accuracy | 72 to 84% | 94 to 98% |
| RCPA accuracy | 68 to 80% | 92 to 96% |
| Territory route adherence | 68 to 80% | 88 to 94% |
| MR attrition | 28 to 42% annual | 20 to 30% |
| Per-MR productive selling time | 3.5 to 4.5 hours | 5.5 to 6.5 hours |
Compliance and regulatory layer
| Regulatory framework | Implication for pharma field force |
|---|---|
| UCPMP (Uniform Code for Pharmaceutical Marketing Practices) | Sample distribution limits, promotional gifts ban, content discipline |
| NMC / MCI guidelines for HCP engagement | Documentation of all doctor interactions |
| NPPA pricing oversight | Price compliance at chemist level |
| CDSCO drug control | Sample tracking and batch traceability |
| DPCO scheduled drug compliance | Distribution and inventory verification |
| SEBI BRSR Core (listed pharma) | Value chain disclosure for vendor and field force |
| Companies Act 2013 IFC | Internal financial controls over field force spend |
| FCPA and UK Bribery Act (exporters) | Verified compliance evidence for global listing |
FEI compliance deliverables
| Compliance deliverable | FEI output |
|---|---|
| Per-call audit log | MR, doctor, time, duration, materials shared |
| Sample chain of custody | Per-pack tracking from stock to drop |
| Promotional content discipline | e-detailing content version log |
| UCPMP self-attestation evidence | Quarterly verified compliance scorecards |
| Audit committee finding closure | Substantiable evidence for IFC findings |
| BRSR Core value chain disclosure | Field force and vendor verified records |
| Anti-bribery and corruption documentation | Doctor engagement audit-grade trail |
| External auditor support | 7-year retained evidence accessible on demand |
Field force allocation rebalancing: the Kearney lever
| Reallocation scenario | Current state | Post-rebalancing |
|---|---|---|
| MR count in low-productivity territories | 22 to 30% of force | 10 to 15% |
| MR count in high-potential territories | 50 to 60% | 65 to 75% |
| Average sales per MR per quarter | ₹18 to 32 lakh | ₹26 to 45 lakh |
| High-potential doctor coverage | 64 to 76% | 88 to 95% |
| MR attrition in over-allocated regions | 32 to 42% | 22 to 28% |
| Field force ROI | 2.2 to 3.5x | 3.5 to 5.5x |
e-detailing and digital engagement
| e-detailing capability | FEI integration point |
|---|---|
| Tablet-based product detailing | Session log with timestamp and duration |
| Doctor engagement scoring | Slide-by-slide interaction logged |
| Content version control | Always-current MR-approved content |
| Compliance-locked content | UCPMP-aligned versions only |
| Follow-up triggers | Auto-task generated post detailing |
| Hybrid in-person plus digital | Cross-channel doctor engagement view |
| Multi-language content delivery | Regional language and accent support |
| e-prescribing platform integration | Direct prescription correlation |
Real-time decision infrastructure for pharma SFE
| Decision point | Pre-FEI cadence | FEI cadence |
|---|---|---|
| Territory rebalancing | Annual | Quarterly |
| MR performance intervention | Monthly review | Weekly anomaly inbox |
| Doctor coverage gap detection | Quarterly | Real-time dashboard |
| Sample distribution adjustment | Quarterly | Weekly |
| RCPA-driven brand strategy | Half-yearly | Monthly |
| Field force expansion or contraction | Annual budgeting | Quarterly with verified ROI data |
| POB scheme effectiveness | Quarterly | Weekly |
| Compliance audit response | Reactive | Continuous monitoring |
Sample ROI math for a mid-sized pharma company
| Line item | Pre-FEI | Year 1 of FEI |
|---|---|---|
| Field force size | 2,400 MRs | 2,400 MRs |
| Annual field operating cost | ₹280 Cr | ₹280 Cr |
| Unverified or unproductive share | 26% | 11% |
| Recovered productive capacity | -- | ₹42 Cr equivalent |
| A-grade doctor coverage uplift | -- | +22 percentage points |
| Sample leakage | 9 to 12% | 2 to 4% |
| RCPA reliability | 72% | 94% |
| Prescription lift attributable to verified coverage | -- | 4 to 7% revenue impact |
| Platform cost (annual) | -- | ₹4 to 7 Cr |
| Net P&L impact (Year 1) | -- | +₹35 to 55 Cr |
Legacy SFA vs FEI: the architectural shift
Legacy SFA / MR reporting stack
DCR self-submission, MTP planning, GPS check-in, expense tracking, manager review. Verification gaps absorbed as activity noise. Visit adherence at 30 to 40% reality vs 88 to 96% reported. Compliance evidence inconsistent. Sample reconciliation quarterly.
FEI execution stack
9-layer verification, sensor cross-check, face match, RCPA OTP, sample chain of custody, prescription correlation, UCPMP-aligned audit trail, BRSR Core ready retention. Visit adherence rises to 88 to 94% verified. Compliance audit-grade. Sample leakage drops below 4%.
In Indian pharma, the question is no longer how many calls were made. The question is whether the planned doctors were actually covered, whether the conversation actually happened, and whether the field investment is producing prescription lift in the territories that matter.
90-day pharma FEI rollout playbook
| Phase | Duration | Outcome |
|---|---|---|
| Pilot scope and division selection | Days 1 to 10 | One therapy team or one zone selected, KPIs locked |
| MR onboarding and training | Days 11 to 25 | Field force trained on workflow, dashboards live for managers |
| First verified DCRs flow | Days 26 to 40 | Baseline coverage gap quantified, ghost call patterns surface |
| RCPA verification activation | Days 41 to 55 | Chemist OTP integration, audit reliability rises |
| Sample reconciliation integration | Days 56 to 70 | Per-MR sample balance visible, leakage quantified |
| Prescription correlation activated | Days 71 to 85 | Doctor-level call-to-Rx data emerges |
| Closeout assessment shared with leadership | Days 86 to 90 | Side-by-side reported vs verified review with CXO |
| Roll-out planning for full field force | Day 90 onward | Roadmap to 70 to 95% MR coverage in next 6 months |
CFO scorecard for pharma finance heads
| CFO question | Pre-FEI answer | Post-FEI answer |
|---|---|---|
| What is our verified field execution rate? | Unknown | Quantified per division, per region |
| What is our annual field force productivity leak? | Estimated | Quantified in rupees |
| Can we substantiate sample distribution to auditors? | Partial | Per-pack chain of custody |
| What is our UCPMP audit readiness? | Self-attestation | Independently verified evidence |
| Can we defend MR expense reimbursements? | Receipt-based | Receipt plus verified visit linkage |
| How do we measure ROI per MR? | Sales output | Verified coverage to Rx-lift coefficient |
| What is our exposure on territory mis-allocation? | Unknown | Quarterly rebalancing data |
| BRSR Core value chain readiness | None | 7-year audit trail aligned |
Year-on-year trajectory under FEI
| Metric | Baseline | Year 1 | Year 3 |
|---|---|---|---|
| MTP verified adherence | 62 to 78% | 84 to 90% | 92 to 96% |
| A-grade doctor coverage | 64 to 76% | 85 to 92% | 94 to 97% |
| Productive call rate | 52 to 68% | 72 to 80% | 82 to 88% |
| Sample leakage | 9 to 12% | 3 to 5% | 1 to 2% |
| MR productive selling time | 3.5 to 4.5 hrs | 5.5 to 6 hrs | 6 to 6.5 hrs |
| MR attrition | 28 to 42% | 20 to 28% | 16 to 22% |
| Field force ROI | 2.2 to 3.5x | 3.2 to 4.5x | 4.5 to 6x |
| Compliance audit findings | 4 to 7 open | 1 to 2 open | 0 open |
FAQ
Frequently Asked Questions
Glossary
Field Execution Intelligence (FEI)The category of platforms producing verified execution data for India's pharma field force. The 5-layer operating standard for accountable pharma sales operations.
Medical Representative (MR)The field sales force unit in pharma. Visits doctors, chemists, hospitals, and distributors to drive prescription and secondary sales. 600,000+ active MRs in India.
Daily Call Report (DCR)Per-day MR submission detailing doctor and chemist visits, samples distributed, POB taken, and outcomes. The core unit of pharma field reporting.
Monthly Tour Plan (MTP)Forward-looking MR plan covering daily and weekly coverage. MTP adherence is a primary SFE KPI.
RCPA (Retail Chemist Prescription Audit)MR-conducted audit of prescription patterns at chemist counter to track brand share and competitive activity. Weekly verification critical for territory intelligence.
POB (Prescription Order Booking)Secondary order capture by MR at chemist, routed through distributor. Connects MR activity to secondary sales.
e-detailingTablet-based digital product detailing to doctors. Replaces or supplements visual aids with interactive content and engagement tracking.
UCPMPUniform Code for Pharmaceutical Marketing Practices. India's regulatory framework for ethical pharma marketing including sample distribution and HCP engagement.
CDSCOCentral Drugs Standard Control Organisation. India's national regulator for drug control and pharmaceutical quality.
NPPANational Pharmaceutical Pricing Authority. Oversees price control on scheduled and non-scheduled drugs.
DPCODrug Prices Control Order. Schedules ceiling prices for essential medicines and drugs.
SFE (Sales Force Effectiveness)The discipline of optimising MR productivity, coverage, and prescription impact. The metric system pharma sales operations are organised around.
A, B, C, D doctor classificationStandard prescriber tiering by prescription potential. A-grade doctors are top 10%, B is next 20%, C is next 40%, D is bottom 30%.
First Line Manager (FLM) or Area Business Manager (ABM)Direct manager of 8 to 12 M₹The first-level supervision layer in pharma field force.
Productive call rate (PCR)% of doctor calls resulting in detailing of strategic brand or generating Rx commitment. Quality metric for MR effectiveness.
Sample chain of custodyPer-pack tracking from stock issuance to MR, to doctor drop, with evidence at each transition. Compliance requirement under UCPMP.
Ground TruthWhat actually happened on the ground, independently verified. The reference state pharma FEI moves field forces toward.
Blind TrustLegacy operating standard treating self-reported DCRs as evidence. The structural condition FEI replaces.
See actual field coverage vs reported coverage
Bring one division or one therapy team for a 14-day pilot. We deploy the 5-layer FEI stack passively. You receive a verified DCR audit, territory coverage gap report, and sample reconciliation summary. Free, no setup required for M₹
22–38%
Typical MTP gap
5–9x
Year-1 ROI
14 days
Onboarding time
Written by
G
gOGig Editorial
Editorial Team, gOGig
gOGig Editorial covers platform education, field execution intelligence, and operational transparency for India's physical economy workforce.
Was this article helpful?
Your feedback helps us write better content.
